BioSpace News Archive

Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray.

NeuroSense Therapeutics Ltd. today announced positive preliminary results from a novel biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Parkinson’s disease (PD), the second most common neurodegenerative disorder.

In another first, Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, announces Voice Controls, a new feature powered by artificial intelligence (AI) that enables clinicians to control multiple imaging functions with voice commands, leaving their hands free to perform procedures and exams.

Verismo Therapeutics, a clinical-stage CAR-T company and University of Pennsylvania spinout developing novel KIR-CAR platform technology, today announced that it has activated its STAR-101 Phase 1 clinical trial at the University of Pennsylvania.

CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS) from its partner Travere Therapeutics.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the Food and Drug Administration has issued a 510(k) clearance for the Kurin product line. Kurin now has four 510(k) clearances from the FDA.

Tay Therapeutics, focused on developing small molecules for oncology and severe inherited diseases, today announced that it has entered into an exclusive license agreement with VYNE Therapeutics Inc. (Nasdaq: VYNE),

Today, the U.S. Food and Drug Administration is taking additional steps to support the use of decentralized clinical trials (DCTs) for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites.

Interactive Strength Inc. (FORME) (Nasdaq: TRNR), a digital fitness platform that combines premium connected fitness hardware products with personal training and coaching, today announced the closing of its initial public offering of an aggregate of 1,500,000 shares of its common stock at a price to the public of $8.00 per share.

Aurinia Pharmaceuticals Inc. announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V lupus nephritis, a serious complication of systemic lupus erythematosus.